Analyst Price Targets — TIL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 6, 2026 5:18 pm | — | Robert W. Baird | $7.00 | $6.52 | TheFly | Instil Bio downgraded to Neutral from Outperform at Baird |
| September 16, 2024 10:01 am | Jack Allen | Robert W. Baird | $180.00 | $65.58 | StreetInsider | Baird Reiterates Outperform Rating on Instil Bio Inc (TIL) |
| September 16, 2024 6:54 am | Mitchell Kapoor | H.C. Wainwright | $120.00 | $84.52 | StreetInsider | Instil Bio Inc (TIL) PT Raised to $120 at H.C. Wainwright |
| September 12, 2024 7:26 am | Mitchell Kapoor | H.C. Wainwright | $40.00 | $39.19 | StreetInsider | Instil Bio Inc (TIL) PT Raised to $40 at H.C. Wainwright |
| April 12, 2024 2:30 am | Kelly Shi | Jefferies | $11.00 | $11.06 | StreetInsider | Jefferies Downgrades Instil Bio Inc (TIL) to Hold, 'Company Exploring New Avenues Beyond TILs' |
| December 12, 2022 10:44 am | — | Morgan Stanley | $2.00 | $0.84 | Benzinga | Morgan Stanley Maintains Equal-Weight on Instil Bio, Lowers Price Target to $2 |
| June 5, 2022 1:46 pm | Vikram Purohit | Morgan Stanley | $9.00 | $6.01 | TheFly | Instil Bio price target lowered to $9 from $14 at Morgan Stanley |
Latest News for TIL
50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients…
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TIL.
U.S. House Trading
No House trades found for TIL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.